Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
183.50
-2.50 (-1.34%)
Dec 19, 2025, 1:30 PM CST
-5.17%
Market Cap31.33B
Revenue (ttm)42.59M
Net Income (ttm)-433.41M
Shares Out168.46M
EPS (ttm)-2.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume156,096
Average Volume262,019
Open184.00
Previous Close186.00
Day's Range182.50 - 186.00
52-Week Range122.00 - 329.50
Beta0.11
RSI37.34
Earnings DateMar 10, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 43
Stock Exchange Taipei Exchange
Ticker Symbol 6535
Full Company Profile

Financial Performance

In 2024, Lumosa Therapeutics's revenue was 39.15 million, a decrease of -31.21% compared to the previous year's 56.92 million. Losses were -424.78 million, 78.4% more than in 2023.

Financial Statements

News

There is no news available yet.